FRIDAY, June 21, 2024 -- An experimental cancer treatment regimen is achieving full remissions in some patients with aggressive B-cell lymphoma,...
Vous n'êtes pas connecté
June 20, 2024 -- Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer...
FRIDAY, June 21, 2024 -- An experimental cancer treatment regimen is achieving full remissions in some patients with aggressive B-cell lymphoma,...
Researchers from the University of Helsinki and HUS investigated the effects of recurring mutations in the KLHL6 gene in diffuse large B-cell...
THURSDAY, June 20, 2024 -- For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with...
Society of Nuclear Medicine and Molecular Imaging Annual Meeting Cleveland Clinic researchers have discovered a new location for a protein that helps...
Brigham and Women's Hospital researchers have developed a promising "dual action" treatment for lung cancer that combines immunotherapy with...
Researchers have found that longer-lasting heat waves can be deadlier and can pose unique health risks.
The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details best practices for using radiation therapy...
Breast cancer is a complex disease with varying degrees of severity and treatment approaches. Central to understanding and managing breast cancer is...
WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory...
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular...